← Trials/Trial dossier/NCT05221229
GOAL-AF
Active not recruitingOutcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Feasibility Study of GLP-1 Analogues for the Optimization of Outcomes in High BMI Patients Undergoing AbLation for Atrial Fibrillation
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
1
Recruiting sites
—
Enrollment
29
actual
Study population
Atrial fibrillation, Obesity / overweight
Key I/E criterion
—
Primary endpoints
•Adherence to Liraglutide by AF patients before•Number of participants recruited over recruitment period [Time Frame-39 weeks]•≥10% weight-loss responders
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
Patients with Atrial Fibrillation and risk factors defined by eligibility criteria planning to go for AF ablation in Queen Elizabeth Hospital of Birmingham will be approached to enrol in our study.
Inclusion criteria
Patients with symptomatic paroxysmal or persistent Atrial Fibrillation on the waiting list for AF ablation at Queen Elizabeth Hospital Birmingham who
1. are more than 18 and less than 80 of age,
2. have paroxysmal or persistent AF,
3. symptomatic: palpitations, shortness of breath, feeling of an irregular pulse or pause in heart activity, light-headedness, or dizziness) despite pharmacological anti-arrhythmic agents (or inability to take medications) therefore making them eligible for ablation therapy,
4. are above BMI- 30 kg/m2
Exclusion criteria
Any one of the followings;
1. unable to undergo CMR,
2. Patients who are currently treated with a weight losing drug - including Orlistat, GLP-1 analogues or have had/or awaiting bariatric surgery,
3. Type 1 diabetes,
4. Type 2 diabetes on DPP-IV inhibitor or insulin: as blood sugar will need close monitoring on GLP-1 and insulin,
5. Patients with decompensated liver disease, end-stage renal disease or eGFR <30, NYHA class III/IV heart failure or active malignancy,
6. Any malignancy within the last 2 years except skin malignancies,
7. Pregnancy,
8. Patients with a history of thyroid cancer or pancreatitis,
9. Patients with a needle phobia.
Endpoints (11)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Cardiovascular outcomes
2 endpointsRecurrence of AF after first-time AF ablation during one year follow-up [Time Frame- 52 weeks]
Time frame:52 weeks
Atrial-fibrillation composite
time to event, event
AF burden after first-time AF ablation during one year follow-up [Time Frame-52 weeks]
Time frame:52 weeks
Atrial-fibrillation composite
descriptive
Weight & body composition
2 endpointsAccelerated weight loss by Liraglutide on AF patients before first-time ablation and during one year follow-up [Time Frame- 13 weeks from recruitment and 52 weeks after ablation]
Time frame:13 weeks from recruitment and 52 weeks after ablation
≥10% weight-loss responders
threshold achievement, improvement
Changes in Epicardial Fat Volume as measured on heart MRI(CMR) [Time Frame- at baseline and 13 weeks]
Time frame:Baseline and 13 weeks
change from baseline, improvement
Patient-reported / QoL
1 endpointChanges in patient reported outcome measures (AFEQT- AF Effect on QualiTy of life) [Time Frame- at baseline, 13 weeks from baseline and 52 weeks after ablation]
Time frame:Baseline, 13 weeks from baseline and 52 weeks after ablation
change from baseline, improvement
Safety / tolerability / PK
1 endpointAdherence to Liraglutide by AF patients before and after first-time ablation [Time Frame- 13 weeks before and 52 weeks after ablation]
Time frame:13 weeks before and 52 weeks after ablation
threshold achievement, descriptive
Other clinical outcomes
1 endpointAdherence to Kardia Recording Requirements [Time Frame- 39 weeks]
Time frame:39 weeks
threshold achievement, descriptive
Other (unclassified)
4 endpointsNumber of participants recruited over recruitment period [Time Frame-39 weeks]
Time frame:39 weeks
descriptive
Changes in Left Atrial Fibrosis in percentage [Time Frame- at baseline and 13 weeks]
Time frame:Baseline and 13 weeks
change from baseline, improvement
Changes in AF biomarkers [Time Frame- at baseline and 13 weeks]
Time frame:Baseline and 13 weeks
change from baseline, descriptive
Changes in electro-anatomic mapping data in right atrium [Time Frame -at baseline and 13 weeks]
Time frame:Baseline and 13 weeks
change from baseline, descriptive
Publications (1)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- Pilot and feasibility studies2024 Feb 21PMID38383462doi:10.1186/s40814-024-01454-yvia clinicaltrials gov reference derived + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.